Cybin Provides Corporate Update And Highlights Upcoming Clinical Milestones; Initiation Of Pivotal CYB003 Phase 3 Study In MDD Expected In Mid-2024; Phase 2 Topline Efficacy And Safety Results For CYB004 In Generalized Anxiety Disorder Expected Q4 2024
Cybin Provides Corporate Update And Highlights Upcoming Clinical Milestones; Initiation Of Pivotal CYB003 Phase 3 Study In MDD Expected In Mid-2024; Phase 2 Topline Efficacy And Safety Results For CYB004 In Generalized Anxiety Disorder Expected Q4 2024
Cybin 提供公司最新情況並重點介紹即將到來的臨床里程碑；MDD 的關鍵 CYB003 3 期研究預計於 2024 年中期啓動；預計 CYB004 治療廣泛性焦慮症的 2 期主要療效和安全性結果
- Recent U.S. $150 Million funding round lead by a syndicate of leading biopharmaceutical institutional investors supports advancement of clinical-stage programs CYB003 and CYB004 -
-最近由領先的生物製藥機構投資者組成的集團牽頭的1.5億美元融資支持臨床階段項目 CYB003 和 CYB004 的推進-
- Received U.S. Food and Drug Administration ("FDA") Breakthrough Therapy Designation ("BTD") for CYB003, a proprietary deuterated psilocybin analog in development for the adjunctive treatment of Major Depressive Disorder ("MDD") -
-CYB003 獲得美國食品藥品監督管理局（“FDA”）突破性療法稱號（“BTD”），這是一種專有的氘化迷幻藥類似物，用於重度抑鬱症（“MDD”）的輔助治療-
- Initiation of pivotal CYB003 Phase 3 study in MDD expected in mid-2024 -
-預計將於 2024 年中期啓動針對 MDD 的關鍵 CYB003 3 期研究-
- Phase 2 topline efficacy and safety results for CYB004 in Generalized Anxiety Disorder ("GAD") expected Q4 2024 -
-CYB004 在廣泛性焦慮症（“GAD”）中的第二階段主要療效和安全性結果預計將在 2024 年第四季度出現-
Cybin Inc. (NYSE:CYBN) (Cboe CA:CYBN) ("Cybin" or the "Company"), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative...
Cybin Inc.（紐約證券交易所代碼：CYBN）...
登入免費觀看全文
登入/註冊
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。